Takahashi S, Yamane H, Tani N
Folia Psychiatr Neurol Jpn. 1975;29(3):207-14. doi: 10.1111/j.1440-1819.1975.tb02337.x.
A newly developed assay for monoamine oxidase (MAO) activity in blood platelets (serotonin used as substrate) was applied for the measurement of the enzyme activity in 76 schizophrenic patients. No significant reduction was found in the blood platelet MAO activity in a group of 33 untreated schizophrenic patients, as compared to that in the normal controls. Male patients revealed to have lower enzyme activity than females in the schizophrenic group, as we described previously in the normal subjects. Treatment with phenothiazines caused significant reduction of blood platelet MAO activity, while platelet serotonin content and platelet count appeared to be not affected by the drug treatment. The authors suggest that blood platelet MAO activity may be related to hormonal factors but not to psychiatric diagnosis of schizophrenia or constitution liable to schizophrenic illnesses.
一种新开发的用于测定血小板单胺氧化酶(MAO)活性的检测方法(以血清素为底物)被用于测量76例精神分裂症患者的酶活性。与正常对照组相比,33例未经治疗的精神分裂症患者组的血小板MAO活性未发现显著降低。正如我们之前在正常受试者中所描述的那样,在精神分裂症组中男性患者的酶活性低于女性。使用吩噻嗪类药物治疗导致血小板MAO活性显著降低,而血小板血清素含量和血小板计数似乎不受药物治疗的影响。作者认为血小板MAO活性可能与激素因素有关,而与精神分裂症的精神病学诊断或易患精神分裂症疾病的体质无关。